科创板第五套标准重启后，首家创新医疗器械IPO获受理

Core Viewpoint - The Shanghai Stock Exchange has accepted the IPO application of Shenzhen Core Medical Technology Co., Ltd., marking it as the first innovative medical device company to be accepted under the newly restarted fifth set of listing standards [1][4]. Group 1: Company Overview - Core Medical is focused on providing artificial heart products and has developed 5 implantable and 6 interventional artificial heart products, with one implantable product already commercialized and two interventional products in the registration approval stage [3]. - The company's first commercialized product, the Corheart6, is the smallest and lightest magnetic levitation implantable artificial heart globally, with the highest cumulative implantation volume and market share in China [3]. Group 2: Financial Status - As of June 30, 2025, Core Medical reported a cumulative undistributed profit of -367 million yuan, indicating it is still in a non-profitable state [4]. - The company aims to raise 1.217 billion yuan through its IPO to support product development, establish an industrialization base for artificial hearts, and enhance its marketing network and digital infrastructure [4]. Group 3: Investment and Market Position - Core Medical has undergone multiple rounds of financing, attracting investments from notable shareholders including Hillhouse Capital, Zhengxin Valley Investment Management, and others [6]. - The acceptance of Core Medical's IPO application under the fifth set of standards exemplifies the Shanghai Stock Exchange's efforts to broaden financing channels for innovative enterprises [5].